We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Potential Brain Tumor Liquid Biopsies Developed

By LabMedica International staff writers
Posted on 20 Nov 2018
Liquid biopsies are fluid samples from patients, for example from the blood or urine, which provide a less invasive way to monitor disease compared to tumor biopsies. More...
A less intrusive test could be hugely beneficial for brain tumors where collecting samples can be difficult and risky for patients.

The detection rate and concentration of cell‐free tumor DNA (cftDNA) in the plasma of patients with glioma are extremely low, making glioma refractory to current plasma‐based liquid biopsy approaches. Recent studies using DNA sequencing of cerebrospinal fluid (CSF) samples showed that the fraction of mutant DNA in CSF was higher than in the plasma of glioma patients.

Scientists from the Cancer Research UK (Cambridge, UK) and their colleagues recruited 13 patients with glioma and analyzed their CSF. DNA was extracted from single aliquots (2 mL) of the pre‐operative CSF samples using the QIAamp circulating nucleic acid kit. The team used untargeted, low‐coverage whole‐genome sequencing (< 0.4×) to detect somatic copy number alterations (SCNAs) in cell‐free DNA in the CSF of glioma patients. Combining analyses of these SCNAs with DNA fragmentation patterns determined using paired‐end sequencing allows detection of cftDNA in CSF using shallow whole‐genome sequencing (sWGS) data.

The team determined the presence of cftDNA in CSF without any prior knowledge of point mutations present in the tumor. They also showed that the fragmentation pattern of cell‐free DNA in CSF is different from that in plasma. This low‐cost screening method provides information on the tumor genome and can be used to target those patients with high levels of cftDNA for further larger‐scale sequencing, such as by whole‐exome and whole‐genome sequencing. SCNAs were detected by sWGS in CSF from five out of 13 patients. Cell‐free DNA fragments are shorter in CSF than in plasma, with > 50% of fragments below 150 bp. CSF cell‐free DNA fragment length distributions showed 10‐bp periodic peaks, which were decreased in samples where SCNAs were detected. SCNAs and DNA fragmentation patterns in sWGS data can enhance tumor detection using CSF samples.

Florent Mouliere, PhD, the first co-author of the study said, “Liquid biopsies are showing great promise for a number of cancer types, but tests for brain tumors have lagged behind due to the low levels of tumor DNA found in body fluids, in particular the blood. Our work shows that a cheap, easily available technique can be used to analyze tumor DNA in cerebrospinal fluid. In the future, we envisage that this technique could be used to identify patients who may benefit from further tests that could help monitor their disease, opening up more tailored treatment approaches.” The study was published on November 6, 2018, in the journal EMBO Molecular Medicine.

Related Links:
Cancer Research UK


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.